HOME >> BIOLOGY >> NEWS
MITs smart surface switches properties reversibly

CAMBRIDGE, Mass.--MIT engineers and colleagues from the University of California are reporting a unique design of a smart surface that can reversibly switch properties in response to an external stimulus. The work paves the way for systems that could, for example, release or absorb cells and chemicals from surfaces on demand.

In the Jan. 17 issue of Science, the researchers describe an example of their new approach in which they engineered a surface that can change from water-attracting to water-repelling with the application of a weak electric field. Switch the electrical potential of that field from positive to negative and the surface reverts to its initial affinity for water.

The general technique, on which the group has filed for a patent, could also be applied to the dynamic control of other surface characteristics such as adhesion, friction and biocompatibility. We started with a fundamental system to prove that the overall concept of reversibly modifying a surface via conformational transitions works, said Thanh-Nga Tran, a graduate student in the Harvard-MIT Division of Health Sciences and Technology (HST) and the Department of Chemical Engineering.

This opens the door to a variety of applications, including novel drug-delivery systems and smart templates for the bioseparation of one molecule from another, said Robert Langer, MITs Germeshausen Professor of Chemical and Biomedical Engineering and leader of the work. Langer has appointments in chemical engineering, HST and MITs Biological Engineering Division.

This is the first time to our knowledge that anyone has created a truly reversible switch of a surfaces property exploiting monomolecular layers, said Joerg Lahann, a Postdoctoral Associate in CE. As a result, we believe this study lays the fundamental groundwork for a new paradigm in surface engineering that may be of considerable significance in materials science, biology, and medicine.

In addition to L
'"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
16-Jan-2003


Page: 1 2 3

Related biology news :

1. Study of flu patients reveals virus outsmarting key drug
2. Muscles are smarter than you think
3. Purdue scientists finding ways to outsmart crop-damaging bugs
4. With natures help, a better vision system for smart weapons
5. UCSD researchers fabricate tiny smart dust particles
6. Scientists at the Scripps Research Institute design gene-tipped tumor regressor smartbombs
7. Researchers developing technology to outsmart metastasized cancers
8. How did we get so smart? Study sheds light on evolution of the brain
9. Pharmaceutical smart bomb targets cancer cells
10. Female birds choose best singers to have smarter offspring
11. Prosthetic limb to be controlled by microchip: Agreement signed to create smart leg

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MITs smart surface switches properties reversibly

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: